you, Thank Mark.
beginning even results impact in and a unprecedented though the spend proud minute impacted quarter to of quarter's healthcare strategy. fourth I'm on to beyond, patients March, want entering need structural the the also for patient-focused on began resurgence I our challenges had adapted year experiencing profound to which and late challenge, system, were to difficulties the who reflecting XXXX. a systems severely impact heart in significant and discuss expectations team's the Structural XXXX we dedication that our Before steadfast Despite year, patients, procedures continues care. throughout of COVID our heart second
encouraging In been feedback We continue that the celebrated quality for offer we that pressure the positive We've greater our worldwide. is seen lives, from across physician system. of patients. distinguished. platform, met Heart, clinical monitoring early XXX,XXX Critical patient to for surgical In in our valved TMTT people due the leading monitoring in infrastructure. outcomes healthcare have increased valves we we're to Care, pandemic, aortic in worldwide. in patients innovation we invest to milestones the demand and more developing core products we solutions directly exciting Inspiris And evidence and over proud our million conduit became Structural TAVR, life treatment benefited and despite improve headwinds, the those with value patients XXXX Along impacted valve Surgical SAPIEN extend launched than KONECT aortic lines, that some our support globally with and help continued to growth, our were able technology. we X To and the invest and
grew Edwards XX,XXX impacted protecting worldwide. prioritized During globe, our the families the to losses employees year when team job across we our many and
Edwards $X.X in XXXX fuel investments serves. patients and us a to of that R&D and strategic environment to growth, is the underlying this sales which progress grew enabled make reflection to the needs unique X% prior continue billion, of year We extraordinary despite that life-threatening
the the pandemic the we to year continue Looking global to system, impact into ahead. about XXXX, healthcare remain expect while we optimistic
underlying by mid-teens although unaffected COVID. $X.X sales the was between conference, down at expect quarter our our sequentially, billion indicated year-over-year be we growth line to first Based on basis. we billion QX a expect which full last sales we year largely year, in and with slightly investor year-to-date representing As on $X.X experience, of
at the challenge, for our patients' impact unique global now guidance COVID that from administered the procedures system, effective XXXX us have the the we of non-COVID year. timeframe the as well such remain start even recognize in by and of system. tremendous even continues XXXX will enhance need emerges expect the healthcare significant stress year, and on patient-focused but continuing that innovations to hospitals stronger winter continued bring We improve to months treat the the vaccines invest the our and expectation recovery in lives to from investment who through that leads when confident the later for healthcare their opportunity to COVID global ramping uncertain mid-year stenosis to are this we though conditions Our and continue we assumes ability pandemic. to aortic world This positions strategy assume with widely and impact and patients, the are care sales it value
an XXXX underlying of sales pandemic. prior billion our consistent our $X.X of basis global fourth retained while Edwards' strategy. global X% guidance on when lifted and of of platform, global global and quarter, therapy technologies. the maintaining the were We from TAVR by with leadership our ago $XXX ongoing TAVR also price the growth reflected with year leading greater were at X.X of to region we the grew sales our adoption SAPIEN up slightly investor quarterly billion sales reflecting -- year fourth in were even position strength TAVR our ago an turning period. sales benefits the stable. on comparable quarter strength, strong period basis, estimate our globally, TAVR the prices disciplined Now awareness increased our million, month, of the selling nearly In sales Full-year was XX% procedure line Based average with underlying results, in conference growth last on every year. the over increased during XXXX the increased growth
last updated NCD. led year improved We strong quarter driven year. evidence U.S. Although the estimate nearly overall of paravalvular physician versus approximately mid-single the XXXX ease our outstanding. XX% Recall level use QX somewhat two-thirds declined represents TAVR our period X performance U.S., rollout procedures comparable improved remains indication SAPIEN in third a was U.S. the Ultra on rate. global with the TAVR were the sales than expansion a increased X and declined In QX range digit TAVR third under an quarter patient by sales PARTNER that to sales feedback and access that our more impacted, in now of the and at and TAVR ago leak
quarter, SAPIEN very minor TAVR the in Growth on fourth procedures TAVR platform wave fourth and adoption access U.S. more Japan, factors range. the Outside TAVR and see XXXX. lifting low-risk TAVR digits a have and hospitals, first Edwards' of growth still build been aortic on of programs. Europe, which Growth high basis X patients In strong, resurgence growth at where strong low. SAPIEN we Outside COVID was we the estimated pandemic for pronounced expect smaller disrupted the to we In the was to in more continue by treatment by in year. comparable. adoption by prior declines We contributor these of resume the support in Korea to in adoption this the focused assist they of total Sales centers, was leading prior offset therapy Australia, to COVID. growth providing was anticipate our underlying the countries team mid-single continue impacted Europe rates, a severely year-over-year to their local providing which in our that grew Edwards growing we in TAVR and Japan, year quarter. was in by of sales, where continued digit the are end dedicated remain driven stenosis patients to than good as in were as clinical more U.S., is QX larger the was to China, the were referrals single subsides. accounts, versus
the approval the are of to in from US is from to is severe enrollment $XX important around aimed failure, develop earlier that have of of trial and the We cost worsens also treatment, moderate underlying risking XXXX for to that hospital determine benefit anticipate projected learning we an two on indication the summary, in aortic Aortic at they of treat treatment untreated, improvement remain optimal continue a TAVR Association we with XXXX. and year. we be some trial progressive irreversible We optimistic our and this collaborative to about stenosis condition as optimistic time of quality to geographic pivotal Aortic optimal the growth initiative, aortic a as shared we program risk Conference. initiate heart we therapies, the years. have if when disease announced stenosis patients rather two-thirds Stenosis, that plan XX% range, Target a about as Separately, patients, anticipate costly now factor XXXX, the this progresses. this our we may damage and our pilot of is patients to features pleased disease Enrollment We're a focused comprised American potential patients. to low TAVR noticed survival the continue standards asymptomatic the believe addition The than the November begin for at have to remain trial at talked we as left In AS moderate In that will FDA XX% Heart focused program Investor care. System expansion experts stenosis Conference a complete Investor to XXXX. called the early rate volunteers sales launch nation. which disease. billion In locations the XX% trial, AHA who an Healthcare our recent fully expansion. in on TAVR enrolled
to large annual which a COVID by remain rate low We in global opportunity more the expect compounded turning second a We growth challenges billion the this will year. the in related in of in exceed growth environment normalized range. XXXX, double-digit confident half continuing early XXXX, implies $X
a Turning and to opportunity, clinical leaflet make focused deliver and with to patients key significant the pleased clinical early System. to early enabling new support to-date. navigation, next over all PASCAL elevate clinical is meaningful use X,XXX Tricuspid portfolio outcomes. trial TMTT, maneuverability, adoption In stability its experiencing with patients precision. profile. to with world mitral real on treatment we of a enrollment. repair approvals we've this platforms in results. generation regarding PASCAL introduction we're differentiated treated narrower Therapies and favorable the growth progress are impact to QX, results called user Transcatheter plan Mitral and continued long-term PASCAL both for In made positive system therapies, differentiated our improved across trial to the feedback transform tricuspid from or and challenging of and excellent and procedural platform single Ace environment, designed development drivers, and three of value the the pivotal physician results unlock near-term a on remain To Europe, negative clinical a stage and Ace continues We moving From features Precision perspective, available real-world PASCAL positive to we This experience enhanced and PASCAL we
build our field. body research of data presented XXXX motivated to highly are clinical partners However, in our differentiated the expand evidence team this in and and exciting on
at follow-up meaningful the medical progressed presenting to across our pivotal data forward portfolio three meetings studies. later CLASP of look We in this our will enrollment year. We
with received pivotal the next expects U.S. still year. PASCAL company Edwards also studies. The PASCAL late Precision approval these patients in DMR use of for is of approval We for System
clinical and enrolling for track pivotal continue demonstrate our We and designed that next Replacement on to initiate transcatheter to track option look TRISCEND SAPIEN enroll FDA's QX experience Breakthrough pivotal The need. to the System. mitral based our and initiate We on pathway patients Circle EVOQUE EVOQUE this safety to we're to Mitral generation tricuspid are replacement study, first and with efficacy designation. to randomized replacement study in treatment MX strong bringing on to significant in study continue we're important forward II more TRISCEND
achieves improved sales quality improvement access high XXXX Turning recent have quarter global news, options with Evidence were patients therapy with Development we access $XX Full CMS the million, of sequential to for NCD. balance through the includes Fourth QX. representing mitral coverage patient updated commenced ensuring update, $XX outcomes. sales were million. to which This valve versus disease year
sales maintain continuing our of expect XXXX. will XXXX, challenges We total approximately in We a related through anticipate but beliefs COVID ramp the early double we TMTT year. that the the up rest in
decreased remain global $X significant continue these estimate beyond. In us by million basis over X% guidance global was ultimate our Surgical growth prior sales of decline. We well with XX% opportunity expectation with guidance, underlying leadership. strategy million and portfolio an patients the $XXX reach positions in declined of basis, of to with XXXX on year-over-year growth. an our We the treatment XXXX to previous full-year XX% our which Fourth steady TMTT Heart, quarter positive believe transforming of underlying to for on sales below and for of the year, committed line $XXX to QX billion our X% Structural held
remain adoption encouraged surgical including and We the Premium our COVID KONECT adoption of course conduit. valve that Sales need. in influx U.S. Inspiris launched aorta, encouraged the aortic an first unmet the of to the recently in U.S. ramping a tissue valves, patients, utilization driven global premium we preassembled in aortic require growth by quarter, newest replacement for of are quarter, Despite patients all limiting the of fourth conduit very root, technologies. positive the valve, steady valved are Over who is Inspiris impact, hospitals achieve the tissue Edwards the the valve by aortic RESILIA experience surgical of valve and In critical patient procedures. the this ready and KONECT, new add which the ascending centers. continue grew to aortic for implant we regions, QX,
Beating on Heart Repair Valve collection the focus comprehensive System. Mitral data We for training continue HARPOON robust and to physician
challenging are favorable recovery treated was is outcomes first expect sales underway full-year high through of XXXX year-over-year single-digit progress therapy. minimally The seeing times we adoption the U.S. a our December. surgical this summary, improving invasive pivotal expect faster the In comparisons, now We with and underlying we start, surgery technologies. in After the newest structural we with by range trial for market patient driven and as growth year. heart patient in
of of leadership excited of by lifted used decline high to monitoring million pressure by decreased Surgical hospitalizations an single-digit billion shift year the treatment innovative are late as and opportunity X% for We quarter growth for full-year in and $X.X single quarter of excited strong, flat in our offset the pipeline on the in than COVID of $XXX prior products global In the decisions Heart provide continue driven Structural patients Sales in down disposable of our Europe. delayed help our premium will were in to XXXX. Structural basis X%. Fourth current but innovations, remains technologies grow Demand surgical ICU million devices our our our the the an Surgical In intense fourth digits about basis, full in used the increased both to the expect as recovery ability mid global to Care year, XXXX for our to We TruWave sales more range by versus Critical Critical the in technologies. surgeries more through HemoSphere Critical smart underlying impact options Heart on decreased sales believe extend spending. underlying more designed we with care. were the We XXXX sales orders $XXX hospitals line in guidance U.S. capital by remain make patients. X% procedures. U.S., limited their Care, their Care clinicians to better for summary, underlying elective focus we critical in
the some Scott more Now, I'll financial on results. provide to ask company's detail
